For instance, in SA-ARDS patients with elevated levels of CRP and IL-6, the application of tocilizumab (a humanized monoclonal antibody targeting the IL-6 receptor) has been shown to effectively reduce the probability of intubation and decrease mortality risk in ARDS patients (86, 87). Here, IL6 is linked to acute respiratory distress syndrome.